Chemoenzymatic Synthesis of Pyrrolo[2,1-b]quinazolinones: Lipase-Catalyzed Resolution of Vasicinone
摘要:
A facile synthesis of bronchodilatory pyrrolo [2,1-b] quinazoline alkaloids by azidoreductive cyclization strategy employing TMSCl-NaI and bakers' yeast is described. Both the chemical and enzymatic methods are mild and take place at room temperature in good yields. Further, synthesis and resolution of vasicinone has been carried out by employing different lipases. It has been observed that lipase PS provides acetate of (S)-vasicinone in 98% ee.
[EN] NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE TOXINE DE CLOSTRIDIUM DIFFICILE
申请人:VENENUM BIODESIGN LLC
公开号:WO2017214359A1
公开(公告)日:2017-12-14
The present invention relates to benzodiazepine derivative compounds of formula (I), or pharmaceutically acceptable salts thereof. The present benzodiazepine compounds are useful Clostridium difficile inhibitors in the treatment of Clostridium difficile infection in humans. The present invention provides a pharmaceutical composition containing benzodiazepine compounds of formula (I) and a method of making as well as a method of using the same in treating patients infected with Clostridium difficile infection by administering the same. The compounds of the present invention may be used in combination with additional antibiotics or anti-toxin antibody drugs.
The total synthesis ofrutaecarpine and several analogues has been developed by using an azido reductivecyclization process starting fromsubstituted azido benzoicacids. The intramolecular azido reductivecyclization step was performed with triphenylphosphine or Ni 2 B in HCl―MeOH (1 M) using microwave irradiation. This synthetic route is amenable for the generation of a library of quinazolinone compounds
已经通过使用从取代的叠氮基苯甲酸开始的叠氮基还原环化过程开发了芸香果芸香碱和几种类似物的全合成。分子内叠氮基还原环化步骤使用三苯基膦或 Ni 2 B 在 HCl-MeOH (1 M) 中使用微波辐射进行。该合成路线适用于生成喹唑啉酮化合物库。
Benzoheterocyclic fungicides
申请人:SCHERING AGROCHEMICALS LIMITED
公开号:EP0247760A3
公开(公告)日:1989-05-31
Compounds of any one of formulae I - VII
where.... is a single or double bond;
A is oxygen or sulphur;
R¹ is aryl;
R² is 1-imidazolyl or 1,2,4-triazol-1-yl; and
R³, R⁴, R⁵ and R⁶ which may be the same or different, are each hydrogen, halo, alkyl or alkoxy, have fungicidal activity.
公式I - VII 中的任何一种化合物,其中....是单键或双键;A是氧或硫;R¹是芳基;R²是1-咪唑基或1,2,4-三唑-1-基;以及R³、R⁴、R⁵和R⁶可能相同也可能不同,分别是氢、卤素、烷基或烷氧基,具有杀真菌活性。
Identification and initial optimization of inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB)
作者:Jeffrey J. Letourneau、Ilana L. Stroke、David W. Hilbert、Laurie J. Sturzenbecker、Brett A. Marinelli、Jorge G. Quintero、Joan Sabalski、Linh Ma、David J. Diller、Philip D. Stein、Maria L. Webb
DOI:10.1016/j.bmcl.2018.01.005
日期:2018.2
The discovery, synthesis and preliminary structure-activityrelationship (SAR) of a novel class of inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB) is described. A high throughput screening (HTS) campaign resulted in the identification of moderately active screening hits 1–5 the most potent of which was compound 1 (IC50 = 0.77 µM). In silico docking of an early analog offered suggestions
The present invention relates to benzodiazepine derivative compounds of formula (I), or pharmaceutically acceptable salts thereof. The present benzodiazepine compounds are useful Clostridium difficile inhibitors in the treatment of Clostridium difficile infection in humans. The present invention provides a pharmaceutical composition containing benzodiazepine compounds of formula (I) and a method of making as well as a method of using the same in treating patients infected with Clostridium difficile infection by administering the same. The compounds of the present invention may be used in combination with additional antibiotics or anti-toxin antibody drugs.